[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The Second Affiliated Hospital of Chongqing Medical University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":484},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,21,0,[8,40,68,90,124,149,170,183,203,225,247,265,292,314,334,354,379,400,417,441,462],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100638849","phase-4-asc22-combined-with-peg-ifna-in-achieving-functional-cure-in-patients-with-chronic-hepatitis-b-virus-infection-100638849",false,"NCT07573943","ASC22 Combined With Peg-IFNa in Achieving Functional Cure in Patients With Chronic Hepatitis B Virus Infection","Inclusion Criteria:\n\n1. Body mass index (BMI) of 18 to 32 kg\u002Fm\\^2;\n2. Serum HBsAg\\\u003C100 IU\u002FmL;\n3. HBV DNA\\\u003C20 IU\u002FmL;\n4. HBeAg-negative.\n\nExclusion Criteria:\n\n1. A history of allergy, or who are suspected by the researcher to be allergic to the active ingredient of the drug under study or its excipients;\n2. Use of immunosuppressants, immunomodulators (thymosin) and cytotoxic drugs within 6 months before enrollment, or vaccination of live attenuated vaccine within 1 month before enrollment;\n3. Acute infection within 2 weeks before enrollment which requires intravenous antibiotic treatment, or existing infection which requires anti-infection treatment when enrollment;\n4. Confirmed or suspected decompensated cirrhosis;\n5. Malignant tumors;\n6. Serious diseases of circulatory, respiratory, urinary, blood, metabolic, immune, mental, neurological, renal and other systems;\n7. Hepatitis C virus (HCV) antibody (+), HIV antigen\u002Fantibody (+), or treponema pallidum antibody (+) and rapid plasma regain (RPR) test (+);\n8. Female in suckling period or pregnancy test (+) during screening;\n9. Subjects who are considered by the researcher to have other factors that are not suitable for the study","ALL","18 Years","70 Years",{"count":19,"type":20},150,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","Exploring the safety and efficacy of the therapy combining immune checkpoint inhibitors (anti-PD-L1 monoclonal antibody, ASC22) and pegylated interferon alfa (Peg-IFNα) in patients with CHB. Exploring new combination therapeutic schemes for hepatitis B cure, and raising the overall clinical cure rate to more than 50% without screening specific advantageous groups.",[26],"Chronic Hepatitis b","RECRUITING","2026-05-05",{"date":30,"type":31},"2026-05-07","ACTUAL",{"date":33,"type":31},"2024-05-21",{"date":35,"type":20},"2026-12-31",{"name":37,"class":38},"The Second Affiliated Hospital of Chongqing Medical University","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":47,"enrollmentInfo":48,"targetDuration":50,"studyType":51,"phases":4,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":4},"100634004","impact-of-metabolic-disorders-on-cacld-outcomes-100634004","NCT07534046","Impact of Metabolic Disorders on cACLD Outcomes","Impact of Metabolic Disorders on Clinical Outcomes in Patients With Compensated Advanced Chronic Liver Disease: A Multicenter, Prospective, Cohort Study","Inclusion Criteria:\n\n* Voluntary signing of written informed consent;\n* Aged between 18 and 75 years (inclusive of 18 and 75), both genders eligible;\n* Evidence of liver cirrhosis by imaging (including ultrasonography, CT, MRI), or pathological findings indicating F3\u002F4 fibrosis, or Liver Stiffness Measurement (LSM) ≥10 kPa as measured by VCTE;\n\nExclusion Criteria:\n\n* Decompensated cirrhosis at baseline, defined as having experienced any of the following three conditions within the past year: ① History of variceal bleeding; ② Moderate to severe ascites; ③ Overt hepatic encephalopathy;\n* Prior or current diagnosis of hepatocellular carcinoma or other malignancies that cannot be treated with curative intent, with an expected survival of less than 1 year;\n* Previous orthotopic liver transplantation;\n* Concurrent hematological and lymphatic system diseases;\n* Concurrent severe dysfunction of vital organs such as the heart, lungs, brain, and kidneys:\n\nHistory of pulmonary diseases: Severe pulmonary diseases that significantly affect lung function, such as severe emphysema, pulmonary embolism;\n\nHistory of severe heart disease, meeting one of the following criteria:\n\n1. Decompensated cardiac insufficiency (New York Heart Association \\[NYHA\\] Class III-IV);\n2. Unstable angina pectoris; Chronic Kidney Disease (CKD) stage ≥3 (defined as baseline serum creatinine exceeding 177 μmol\u002FL);\n\n   * Pregnant or breastfeeding women;\n   * Judged by the investigator to be unsuitable for participation in this study.","75 Years",{"count":49,"type":20},4307,"5 Years","OBSERVATIONAL","This multicenter, prospective, cohort study is designed to investigate how metabolic disorders (such as obesity, diabetes, and high cholesterol) influence the progression of liver disease in patients with compensated advanced chronic liver disease (cACLD). Chronic liver disease often progresses silently for many years before serious complications like liver failure, cancer, or variceal bleeding develop. While it is known that metabolic problems can accelerate liver damage, current tools for predicting individual risk remain limited. This study aims to enroll approximately 4,307 adults with cACLD from six major medical centers across China. Participants will undergo regular follow-up every 3 to 6 months for up to 5 years, during which routine clinical assessments, non-invasive imaging (including MRI elastography), metabolic health indicators, and biological samples will be collected. No experimental treatments are provided; participants receive standard medical care as determined by their physicians. The primary goal is to determine whether metabolic abnormalities are linked to serious liver-related events including ascites, variceal bleeding, hepatic encephalopathy, liver cancer, liver failure, and liver-related death. The study will also evaluate how advanced imaging techniques predict these complications and develop a comprehensive risk prediction model integrating metabolic factors, imaging results, and traditional liver function tests. By better understanding the role of metabolic health in liver disease progression, this research may help identify new intervention targets and improve the ability to predict which patients are most likely to develop serious complications, ultimately leading to more personalized care and better outcomes for individuals with chronic liver disease.",[54],"Compensated Advanced Chronic Liver Disease",[56,57,58],"MRE","cACLD","metabolic disorders","NOT_YET_RECRUITING","2026-04-14",{"date":62,"type":31},"2026-04-16",{"date":64,"type":20},"2026-04-01",{"date":66,"type":20},"2031-12-31",{"name":37,"class":38},{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":75,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":4},"100628696","cohort-study-of-chronic-liver-disease-complicated-by-sepsis-100628696","NCT07465003","Cohort Study of Chronic Liver Disease Complicated by Sepsis","Use of Antimicrobial Drugs in Severe Infections and Epidemiological Study of Populations With Severe Infections","Inclusion Criteria:\n\n* Clinically or pathologically diagnosed with cirrhosis;\n* meets the Sepsis-3 diagnostic criteria.\n\nExclusion Criteria:\n\n* Combined organ transplantation, active malignant tumors;\n* Pregnant or breastfeeding women;\n* Long-term use of immunosuppressants (non-steroidal);\n* Death or voluntary discharge within 24 hours of admission;\n* Incomplete data.",true,{"count":77,"type":20},1600,"Study population: Patients with liver cirrhosis complicated by sepsis Observation indicators: Fluid resuscitation strategy, early dynamic indicators such as MAP Observation endpoint: 28-day all-cause mortality Study design: Retrospective cohort study",[80,81],"Cirrhosis","Sepsis","2026-03-09",{"date":84,"type":31},"2026-03-11",{"date":86,"type":20},"2026-02-25",{"date":88,"type":20},"2028-06-01",{"name":37,"class":38},{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":97,"enrollmentInfo":98,"targetDuration":4,"studyType":21,"phases":100,"briefSummary":102,"conditions":103,"keywords":107,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":39},"100619055","functional-lung-avoidance-radiotherapy-guided-by-4dct-pulmonary-ventilation-function-imaging-a-prospective-single-arm-clinical-study-100619055","NCT07339644","Functional Lung Avoidance Radiotherapy Guided by 4DCT Pulmonary Ventilation Function Imaging: A Prospective Single-arm Clinical Study","4DCT-FLAR","Inclusion Criteria:\n\n* Age 18 to 85 years (inclusive); any sex.\n* Diagnosed lung malignancy requiring thoracic radiotherapy (e.g., non-small cell lung cancer, small cell lung cancer, or pulmonary metastases).\n* Planned to receive thoracic radiotherapy using either conventionally fractionated IMRT\u002FVMAT or stereotactic body radiotherapy (SBRT), and able to complete pre-treatment 4DCT simulation suitable for generating a ventilation map.\n* Adequate baseline organ function and clinically judged able to tolerate radiotherapy; ECOG performance status 0-1.\n* No absolute contraindication to pulmonary function testing; patients with moderate COPD or impaired lung function may be included if the treating team judges radiotherapy to be tolerable.\n* Able to comply with treatment and follow-up assessments.\n* Written informed consent provided.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women. Women of childbearing potential must have pregnancy excluded prior to radiotherapy per institutional practice.\n* Age \\\u003C18 or \\>85 years.\n* Uncontrolled severe cardiopulmonary disease or other severe comorbidities that make radiotherapy excessively high risk (e.g., decompensated heart failure, unstable cardiopulmonary status, active severe pulmonary infection).\n* Prior high-dose thoracic radiotherapy to the same region such that safe re-irradiation is not feasible.\n* Concurrent other active\u002Fadvanced malignancy requiring priority treatment that would confound study outcomes.\n* Recent participation in another interventional clinical trial or concurrent investigational therapy judged likely to interfere with this study's endpoints.\n* Severe psychiatric, cognitive, or other conditions that prevent cooperation with radiotherapy and\u002For scheduled follow-up.\n* Inadequate 4DCT image quality or inability to generate\u002Fvalidate the 4DCT ventilation map required for functional-lung-guided planning.\n* Any other condition deemed unsuitable by the investigators in the interest of participant safety.","85 Years",{"count":99,"type":20},100,[101],"NA","This prospective, single-center, single-arm study will evaluate the feasibility and safety of 4DCT ventilation functional imaging-guided functional lung avoidance radiotherapy (FLAR) in patients with lung malignancies receiving IMRT radiotherapy.\n\nAll participants will undergo 4DCT simulation as part of routine radiotherapy preparation. A ventilation map will be generated from 4DCT data, and the top 80% ventilation region will be defined as the high-function lung. This structure will be imported into the treatment planning system to create an FLAR plan that prioritizes sparing of high-function lung while maintaining target coverage (PTV D95%) and meeting standard dose constraints for organs at risk. A conventional anatomic plan (without functional guidance) will also be created for paired, within-patient dosimetric comparison.\n\nThe primary outcome is improvement in dosimetric sparing of the high-function lung (V10, V20, V30, and mean lung dose). Secondary outcomes include the incidence of grade ≥2 radiation pneumonitis (CTCAE v5.0), changes in pulmonary function (e.g., FEV1 and DLCO), and lung-related quality-of-life scores. Assessments will be performed mid-treatment (after 15 fractions), at the end of radiotherapy (after 30 fractions), and at 1, 3, 6, and 12 months after radiotherapy. The study plans to enroll 100 participants and follow each participant for 12 months.",[104,105,106],"Lung Cancer (Including Metastatic Cancer)","Radiation Pneumonitis","Radiation-induced Lung Injury",[108,109,110,111,112,113,114,115],"Functional lung avoidance radiotherapy","4DCT ventilation imaging","Functional lung imaging (FLI)","Dose-volume histogram (DVH)","High-function lung","Radiotherapy planning optimization","Radiation pneumonitis","Pulmonary function","2026-02-05",{"date":118,"type":31},"2026-02-09",{"date":120,"type":31},"2025-10-24",{"date":122,"type":20},"2027-12-24",{"name":37,"class":38},{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":47,"enrollmentInfo":131,"targetDuration":4,"studyType":21,"phases":133,"briefSummary":134,"conditions":135,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":148},"100619825","underdilated-stent-technique-improves-post-tips-encephalopathy-100619825","NCT07349654","Underdilated-stent Technique Improves Post-TIPS Encephalopathy","Underdilated-stent Technique Improves Post-transjugular Intrahepatic Portosystemic Shunt Encephalopathy: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Liver cirrhosis, defined by clinical manifestations, biochemical indicators, imaging examinations, or liver biopsy;\n* History of esophagogastric variceal bleeding, or refractory\u002Frecurrent ascites;\n* Intended to undergo TIPS treatment.\n\nExclusion Criteria:\n\n* Non-cirrhotic portal hypertension;\n* Previous treatments that may affect portal pressure, such as TIPS or surgical procedures;\n* History of overt hepatic encephalopathy (West-Haven classification ≥2);\n* Malignant tumors in advanced stages;\n* Concomitant irreversible heart, liver, kidney, or respiratory failure;\n* Unable or unwilling to sign the informed consent form.",{"count":132,"type":20},72,[101],"Transjugular intrahepatic portosystemic shunt (TIPS) is a critical therapeutic approach for managing esophagogastric variceal bleeding and refractory ascites in decompensated cirrhosis patients. To date, hepatic encephalopathy (HE) remains one of the most common complications following TIPS procedures, and prediction and prevention of post-TIPS HE have always been a hotspot in the field of hepatology. However, no reliable clinical studies have confirmed that any drug or intervention can effectively prevent the occurrence of HE episodes following TIPS, including lactulose and rifaximin.\n\nUnderdilated strategy (UDS) was reported as an development technique proposed in recent years for TIPS procedures, which involves using a small-diameter balloon to dilate the puncture tract and subsequently implanted standard-diameter covered stent (e.g., 8 mm). This allows the stent to maintain a smaller diameter shortly after release, thereby reducing the incidence of hepatic encephalopathy during the postoperative period. Over time, the stent gradually dilates to its normal diameter within months. This period coincides with the higher incidence risk of post-TIPS HE, most commonly occurring within 6 months, especially within the first 3 months after TIPS. Therefore, theoretically, UDS can reduce the occurrence of post-TIPS HE. In terms of clinical research, however, there were still no high quality studies reported the advantages of this technique. Current reported clinical studies were all non-randomized controlled trials or retrospective studies, with low-quality evidence and sometimes contradictory findings.\n\nThe aim of this prospective randomized controlled clinical study is to evaluate whether administration of underdilated technology during TIPS can improve postoperative hepatic encephalopathy, without compromising the therapeutic efficacy of portal hypertension complications.",[136,137,138,139],"Liver Cirrhosis","Variceal Bleeding, Cirrhosis","Ascites Hepatic","Hepatic Encephalopathy (HE)","2026-01-09",{"date":142,"type":31},"2026-01-20",{"date":144,"type":31},"2024-11-19",{"date":146,"type":20},"2027-12-31",{"name":37,"class":38},2,{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":153,"acronym":4,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":155,"targetDuration":4,"studyType":21,"phases":157,"briefSummary":159,"conditions":160,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":169,"locationsCount":39},"100498526","phase-2-a-novel-combination-therapeutic-strategy-aiming-to-functional-cure-for-chronic-hepatitis-b-virus-infection-sustained-hbsag-loss-b-100498526","NCT05771402","A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (B)","Inclusion Criteria:\n\n* 1\\) Sign the informed consent form before inclusion and be able to complete the study according to the study requirements;\n* 2\\) From inclusion to 30 days after the last administration of the study drug, male subjects or female subjects of childbearing age are willing to voluntarily take effective contraceptive measures;\n* 3\\) 18-70 years old. The weight of male subjects is not less than 45 kg, and the weight of female subjects is not less than 40 kg. Body mass index (BMI) is within the range of 18-32 kg\u002Fm\\^2;\n* 4\\) NAs-naive\u002FNAs-experienced CHB patients.\n\nExclusion Criteria:\n\n* 1\\) A history of allergy, or who are suspected by the researcher to be allergic to the active ingredient of the drug under study or its excipients;\n* 2\\) Use of inhibitors, inducers or substrates of CYP3A4 within 28 days before enrollment;\n* 3\\) Systematical use of immunosuppressants, immunomodulators (thymosin) and cytotoxic drugs within 6 months before enrollment, or vaccination of live attenuated vaccine within 1 month before enrollment;\n* 4\\) Acute infection within 2 weeks before enrollment which requires intravenous antibiotic treatment, or existing infection which requires anti-infection treatment when enrollment;\n* 5\\) Clinically significant acute and chronic liver disease not caused by HBV infection (judged by reseachers);\n* 6\\) Confirmed or suspected decompensated cirrhosis, including but not limited to: hepatic encephalopathy, hepatorenal syndrome, bleeding from esophageal varices, splenomegaly, ascites, etc, or evidence of progressive liver fibrosis;\n* 7\\) Primary liver cancer, or alpha-fetoprotein (AFP) is greater than 50 ug\u002FL or imaging suggests the possibility of malignant liver lesions, or other malignant tumors or a history of other malignant tumors within 5 years before enrollment (except that the malignant tumors have been completely relieved after treatment and patients have not received additional medical or surgical intervention within 3 years before screening);\n* 8\\) A history of pathological fracture or osteoporosis;\n* 9\\) Gastrointestinal dysfunction or gastrointestinal diseases that might affect the absorption of oral drugs, such as severe gastric ulcer, erosive gastritis, partial gastrectomy, and persistent gastrointestinal symptoms (such as nausea, vomiting, or diarrhea) \\>2 grades;\n* 10\\) Serious diseases of circulatory, respiratory, urinary, blood, metabolic, immune, mental, neurological, renal and other systems;\n* 11\\) Major trauma or major surgery within 3 months before enrollment, or planned surgery during the study period;\n* 12\\) Blood donation\u002Floss ≥ 400 mL within 3 months before enrollment, or given a blood transfusion within 3 months before enrollment, or blood donation\u002Floss ≥ 200 mL within 1 month before enrollment;\n* 13\\) Platelet count\\\u003C90 × 10\\^9\u002FL, white blood cell count\\\u003C3.0 × 10\\^9\u002FL, neutrophil count\\\u003C1.3 × 10\\^9\u002FL, total serum bilirubin\\>2 × upper limit of normal (ULN), albumin\\\u003C30 g\u002FL, creatinine clearance ≤ 60 mL\u002Fmin (calculated by CKD-EPI formula), or international normalized ratio of prothrombin time (INR)\\>1.5 (unless receiving stable anticoagulant therapy);\n* 14\\) Hepatitis C virus (HCV) antibody (+), HIV antigen\u002Fantibody (+), or treponema pallidum antibody (+) and rapid plasma regain (RPR) test (+);\n* 15\\) A history of continuous alcohol abuse within 3 years before enrollment (average daily alcohol consumption exceeds 20 gram);\n* 16\\) A history of drug dependence or drug abuse within 1 year before enrollment;\n* 17\\) Those who have participated in clinical trials of other investigational drugs or medical devices and taken investigational drugs or used medical devices within 3 months before enrollment;\n* 18\\) Female in suckling period or pregnancy test (+) during screening;\n* 19\\) Subjects who are considered by the researcher to have other factors that are not suitable for the study",{"count":156,"type":20},120,[158],"PHASE2","Hepatitis B virus (HBV) infection is a major public health threat in China. At present, a functional cure, also known as clinical cure or sustained Hepatitis B surface antigen (HBsAg) loss, is recommended as the ideal endpoint of HBV treatment. However, HBsAg loss can be achieved in less than 10% of chronic hepatitis B (CHB) patients treated with current available antiviral drug interferon (IFNα) or nucleos(t)ide analogues (NAs) monotherapy. With the support of the national major special funding for infectious diseases from \"11th Five-Year Plan\" to \"13th Five-Year Plan\", we have implemented a pioneer clinical study of sequential combination of IFNα therapy on NAs to treat NAs-treated CHB patients (ie. New Switch Study). This is the world's first clinical trial aiming to functional cure, which increased the rate of HBsAg loss to 15% in the overall population in our study, and to 30-50% among those with lower baseline HBsAg levels. How to further improve the HBsAg loss rate is an urgent issue for us. The key point of achieving functional cure is to reverse the HBV-specific T cell exhaustion and establish the long-term immune control against HBV infection. (Programmed death-1) PD-1\u002Fprogrammed death-ligand 1 (PD-L1) axis blockade has been demonstrated to reinvigorate exhausted CD8+ T cells, and would be a potential strategy to treat chronic HBV infection. In this study, a large multicenter prospective study will be performed to explore the safety and efficacy of a novel combination strategy involving immune checkpoint inhibitor (anti-PD-1 antibody) and IFNα in CHB patients, observe the HBsAg loss rate in NA-treated CHB patients receiving this combination strategy, evaluate the potential of breaking immune tolerance by this strategy, and further assess its efficacy to further improve the clinical cure rate on the basis of New Switch Study. Based on New Switch Study, this study further attempts to reverse T cell exhaustion in CHB patients, explore a novel platform of combination therapy development for clinical cure, and ultimately increase the HBsAg loss rate to higher than 50% in overall patients. The implementation of the project is expected to reduce the burden of HBV infection in China and contribute to the goal of global elimination of hepatitis B and C by 2030 (WHO 2030).",[26,161,162],"Anti-PD-1 Antibody","Peg-IFNα","2025-09-04",{"date":165,"type":31},"2025-09-11",{"date":167,"type":31},"2023-10-10",{"date":35,"type":20},{"name":37,"class":38},{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":174,"acronym":4,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":175,"targetDuration":4,"studyType":21,"phases":176,"briefSummary":177,"conditions":178,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":179,"startDateStruct":180,"completionDateStruct":181,"leadSponsor":182,"locationsCount":39},"100498404","phase-2-a-novel-combination-therapeutic-strategy-aiming-to-functional-cure-for-chronic-hepatitis-b-virus-infection-sustained-hbsag-loss-a-100498404","NCT05769816","A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (A)",{"count":156,"type":20},[158],"Hepatitis B virus (HBV) infection is a major public health threat in China. At present, a functional cure, also known as clinical cure or sustained Hepatitis B surface antigen (HBsAg) loss, is recommended as the ideal endpoint of HBV treatment. However, HBsAg loss can be achieved in less than 10% of chronic hepatitis B (CHB) patients treated with current available antiviral drug interferon (IFNα) or nucleos(t)ide analogues (NAs) monotherapy. With the support of the national major special funding for infectious diseases from \"11th Five-Year Plan\" to \"13th Five-Year Plan\", we have implemented a pioneer clinical study of sequential combination of IFNα therapy on NAs to treat NAs-treated CHB patients (ie. New Switch Study). This is the world's first clinical trial aiming to functional cure, which increased the rate of HBsAg loss to 15% in the overall population in our study, and to 30-50% among those with lower baseline HBsAg levels. How to further improve the HBsAg loss rate is an urgent issue for us. The key point of achieving functional cure is to reverse the HBV-specific T cell exhaustion and establish the long-term immune control against HBV infection. Programmed death-1 (PD-1)\u002F programmed death-ligand 1 (PD-L1) axis blockade has been demonstrated to reinvigorate exhausted CD8+ T cells, and would be a potential strategy to treat chronic HBV infection. In this study, a large multicenter prospective study will be performed to explore the safety and efficacy of a novel combination strategy involving immune checkpoint inhibitor (anti-PD-1 antibody) in CHB patients, observe the HBsAg loss rate in NA-treated CHB patients receiving this combination strategy, evaluate the potential of breaking immune tolerance by this strategy, and further assess its efficacy to further improve the clinical cure rate on the basis of New Switch Study. Based on New Switch Study, this study further attempts to reverse T cell exhaustion in CHB patients, explore a novel platform of combination therapy development for clinical cure, and ultimately increase the HBsAg loss rate to higher than 50% in overall patients. The implementation of the project is expected to reduce the burden of HBV infection in China and contribute to the goal of global elimination of hepatitis B and C by 2030 (WHO 2030).",[26,161],{"date":165,"type":31},{"date":167,"type":31},{"date":35,"type":20},{"name":37,"class":38},{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":189,"targetDuration":191,"studyType":51,"phases":4,"briefSummary":192,"conditions":193,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":39},"100596692","development-and-validation-of-a-risk-prediction-model-for-postoperative-visceral-pain-in-abdominal-surgery-patients-100596692","NCT07048782","Development and Validation of a Risk Prediction Model for Postoperative Visceral Pain in Abdominal Surgery Patients","Inclusion Criteria:\n\n* Patients undergoing elective abdominal surgery under general anesthesia (including gynecological procedures and general surgery such as gastrointestinal, hepatobiliary, etc.);\n* Aged between 18 and 70 years;\n* Classified as American Society of Anesthesiologists (ASA) physical status II-III;\n* Expected surgery duration ≥ 2 hours.\n\nExclusion Criteria:\n\n* History of previous abdominal surgery;\n* Diagnosed with chronic pain;\n* Long-term use of analgesics or other psychotropic medications;\n* Preoperative emergency condition;\n* Presence of severe comorbidities involving major organ systems;\n* Failure to complete postoperative pain follow-up.",{"count":190,"type":20},1135,"2 Days","This study aims to investigate the factors influencing the risk of postoperative visceral pain in patients undergoing abdominal surgery. The goal is to develop and validate a predictive model for assessing the risk of postoperative visceral pain, in order to guide individualized preoperative interventions and pain management strategies.",[194],"Postoperative Visceral Pain","2025-06-24",{"date":197,"type":31},"2025-07-02",{"date":199,"type":20},"2025-07-01",{"date":201,"type":20},"2026-01-30",{"name":37,"class":38},{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":4,"eligibilityCriteria":209,"healthyVolunteers":75,"sex":15,"minAge":16,"maxAge":210,"enrollmentInfo":211,"targetDuration":4,"studyType":21,"phases":212,"briefSummary":213,"conditions":214,"keywords":216,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":222,"leadSponsor":224,"locationsCount":39},"100595553","effect-of-green-light-exposure-at-different-times-on-the-pain-of-subjects-100595553","NCT07033949","Effect of Green Light Exposure at Different Times on the Pain of Subjects","A Randomized Controlled Study on the Effect of Green Light Exposure at Different Times on the Pain of Subjects","Inclusion Criteria:\n\n1. Age range: 18 - 50 years old.\n2. ASA classification: I - III.\n3. Planned to undergo abdominal surgeries requiring general anesthesia and arterial puncture (this is not necessary for the healthy volunteer group).\n4. Obtained informed consent from the patients.\n\nExclusion Criteria:\n\n1. Skin ulceration, allergic reactions, or dermatitis at the tested area.\n2. Long-term use of analgesics or psychiatric medications.\n3. History of color blindness or uncorrected cataracts.\n4. Severe cardiovascular or respiratory diseases, inflammatory disorders, etc.\n5. Failure of the first arterial puncture.\n6. Communication difficulties, etc.","50 Years",{"count":156,"type":20},[101],"Patients who met the criteria and needed to undergo elective surgery via arterial and venous puncture were included in this center. They were randomly divided into three time periods (8:00-9:00, 12:00-13:00, 16:00-17:00) and were exposed to green light (experimental group) and transparent light (control group) respectively. The effects of green light exposure on acute perioperative pain in patients were observed at different times.",[215],"Pain",[217,218],"Acute Pain","Green light",{"date":220,"type":31},"2025-06-27",{"date":199,"type":20},{"date":223,"type":20},"2025-10-19",{"name":37,"class":38},{"id":226,"slug":227,"hasResults":11,"nctId":228,"briefTitle":229,"officialTitle":230,"acronym":4,"eligibilityCriteria":231,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":232,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":234,"conditions":235,"keywords":237,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":241,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":39},"100589649","the-effect-of-serum-calcium-levels-on-postoperative-pain-a-prospective-observational-study-100589649","NCT06957158","The Effect of Serum Calcium Levels on Postoperative Pain: A Prospective Observational Study","The Effect of Serum Calcium Levels on Postoperative Pain in Patients Undergoing Abdominal Surgery: A Prospective Observational Study","Inclusion Criteria:\n\n* Aged 18-70 years old\n* American Society of Anesthesiologists Classification I-III\n* Patients undergoing elective abdominal surgery under general anesthesia\n* Patients participate voluntarily and sign an informed consent form\n\nExclusion Criteria:\n\n* Patients with a history of severe disease\n* Patients with chronic preoperative pain and\u002For long-term analgesic use\n* Patients with hearing disorders or verbal communication difficulties\n* Patients with psychiatric disorders or cognitive dysfunction\n* Patients requiring mechanical ventilation or ICU admission after surgery\n* Patients with a history of substance or alcohol abuse Patients who could not cooperate with the study for any reason",{"count":233,"type":20},350,"This is a prospective observational study. To investigate the effect of serum calcium levels on postoperative pain in patients undergoing abdominal surgery, and to determine whether changes in serum calcium levels are a risk factor for postoperative pain.",[236],"Postoperative Pain",[238,239,240],"Serum calcium levels","Postoperative pain","Ionized calcium levels",{"date":220,"type":31},{"date":243,"type":20},"2025-07",{"date":245,"type":20},"2025-12",{"name":37,"class":38},{"id":248,"slug":249,"hasResults":11,"nctId":250,"briefTitle":251,"officialTitle":251,"acronym":4,"eligibilityCriteria":252,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":253,"targetDuration":4,"studyType":21,"phases":255,"briefSummary":256,"conditions":257,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":259,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":39},"100559885","phase-4-efficacy-and-safety-of-liposomal-bupivacaine-injection-for-paravertebral-nerve-block-in-the-treatment-of-acute-and-chronic-pain-after-thoracoscopic-pneumonectomy-a-multicenter-randomized-double-blind-controlled-clinical-trial-100559885","NCT06569953","Efficacy and Safety of Liposomal Bupivacaine Injection for Paravertebral Nerve Block in the Treatment of Acute and Chronic Pain After Thoracoscopic Pneumonectomy: A Multicenter, Randomized, Double-blind, Controlled Clinical Trial","Inclusion Criteria:\n\n* Participants who scheduled for elective video-assisted thoracoscopic lobectomy under general anesthesia.\n* Participants were 18 years or older.\n* 18 kg\u002Fm2≤BMI≤30 kg\u002Fm2\n* Participants with American Society of Anesthesiology (ASA) physical status I-III.\n* Understand the significance, possible benefits, potential risks of the trial in detail.Understand the procedures and methods of this study.Willing to complete the trial in strict compliance with the clinical trial protocol.Sign the informed consent form voluntarily.\n\nExclusion Criteria:\n\n* with severe cardiovascular and cerebrovascular diseases such as myocardial infarction,unstable angina pectoris,severe cardiac rhythm disorders (second- and third-degree heart block,etc.), New York Heart Association (NYHA) functional class III\u002FIV,Ischemic stroke.\n* with psychiatric disorders (such as schizophrenia,depression,etc.) and cognitive impairment.\n* with sensory disorders such as hyperalgesia.\n* with other bodily pain.\n* allergy to amide-type local anesthetics or any of the trial drugs\n* taking drugs that affect liver metabolism,corticosteroids,benzodiazepines,non-steroidal anti-inflammatory drugs(NSAIDs),opioid agonist-antagonist,central-alpha 2-agonists,anticonvulsants,antidepressants within 72h.\n* with a history of alcohol or opioid abuse.\n* who were pregnant or lactating.\n* who were currently included in another clinical study within 3 months.",{"count":254,"type":20},284,[23],"The goal of this clinical trial is to evaluate the efficacy and safety of liposomal Bupivacaine administered by paravertebral block for the treatment of acute and chronic pain after video-assisted thoracoscopic lobectomy.",[217,258,236],"Chronic Pain",{"date":220,"type":31},{"date":261,"type":31},"2024-08-26",{"date":263,"type":20},"2025-08-31",{"name":37,"class":38},{"id":266,"slug":267,"hasResults":11,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":4,"eligibilityCriteria":271,"healthyVolunteers":11,"sex":272,"minAge":4,"maxAge":4,"enrollmentInfo":273,"targetDuration":4,"studyType":21,"phases":275,"briefSummary":276,"conditions":277,"keywords":280,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":291,"locationsCount":39},"100530547","establishment-and-evaluation-of-prenatal-prevention-and-treatment-strategy-for-nards-100530547","NCT06188195","Establishment and Evaluation of Prenatal Prevention and Treatment Strategy for NARDS","Establishment and Evaluation of Prenatal Prevention and Treatment Strategy for Neonatal Acute Respiratory Distress Syndrome","A predictive model for neonatal acute respiratory distress syndrome was established based on perinatal risk factors.\n\nInclusion Criteria:\n\n1. The pregnant women with a probability greater than 80% in the prediction model of neonatal acute respiratory distress syndrome and agreed to ACS intervention.\n2. Obtaining patient consent.\n\nExclusion Criteria:\n\n1. the pregnant women with a probability of less than 80% in the neonatal acute respiratory distress syndrome prediction model.\n2. The patient refuses.","FEMALE",{"count":274,"type":20},500,[101],"1. A predictive model for NARDS was established based on perinatal risk factors. Multivariate Logistic regression analysis was used to screen the independent prenatal risk factors for NARDS. A Logistic regression model was constructed using the above independent risk factors and quantified in a nomogram to construct a visualization model for prenatal prediction of NARDS.\n2. The role of ACS in the prevention and treatment of ARDS in near-term\u002Ffull-term infants.\n\nFor neonates with a probability greater than 80% in the prediction model of ARDS, at least one ACS was given before the termination of pregnancy. The GC level of cord blood (taken at birth) and the mRNA levels of α-ENaC, Na-K-atpase and SGK1 in nasal epithelium were measured within 2 hours and 1 day after birth in the ACS intervention group and the control group. The occurrence and severity of pulmonary edema, the occurrence and severity of ARDS, and the mortality rate of NARDS were evaluated by lung ultrasound. The indexes of the two groups were compared horizontally and longitudinally.",[278,279],"Acute Respiratory Distress Syndrome","Respiratory Distress Syndrome, Acute",[281,282,283],"Neonatal Acute Respiratory Distress Syndrome","Prediction nomogram","antenatal corticosteroids","2025-06-02",{"date":286,"type":31},"2025-06-04",{"date":288,"type":31},"2024-02-01",{"date":290,"type":20},"2025-12-31",{"name":37,"class":38},{"id":293,"slug":294,"hasResults":11,"nctId":295,"briefTitle":296,"officialTitle":296,"acronym":4,"eligibilityCriteria":297,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":298,"targetDuration":4,"studyType":21,"phases":299,"briefSummary":300,"conditions":301,"keywords":302,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":313,"locationsCount":39},"100580536","effect-of-remote-local-peripheral-nerve-cooling-on-pain-of-arterial-puncture-100580536","NCT06838572","Effect of Remote Local Peripheral Nerve Cooling on Pain of Arterial Puncture","Inclusion Criteria:\n\n1. 18 \\~ 65 years old;\n2. ASA I-II level;\n3. Patients with perioperative invasive arterial blood pressure monitoring;\n4. Right-handed;\n5. Allen test was normal (palm color quickly turned red or returned to normal within 10 seconds after release of ulnar artery pressure);\n6. Participate voluntarily and be able to understand and sign informed consent.\n\nExclusion Criteria:\n\n1. Patients with a history of musculoskeletal, vascular, neurological or psychiatric disorders;\n2. Patients with a history of diabetes or other systemic diseases\n3. Patients who used any analgesic medication within the month before and during the study;\n4. Patients with a history of smoking, alcohol or drug addiction;\n5. Paraesthesia, scar, redness, damage, rash, etc. exist in the skin of the patient in the test area;\n6. Patients whose surgical area overlaps with the cooling treatment or puncture area;\n7. Female subjects are menstruating.",{"count":99,"type":20},[101],"In this project, volunteers will be recruited to cool the superficial skin of the axillary brachial plexus away from the puncture point, resulting in local peripheral nerve cooling, and observe its impact on the pain of arterial puncture.To explore the local peripheral nerve cooling treatment can produce controllable and reversible analgesic effect even if away from the wound, and provide a new nonpharmaceutical analgesic mode for clinical.",[217],[303,304,305],"Skin cooling","arterial puncture","analgesia","2025-05-25",{"date":308,"type":31},"2025-05-30",{"date":310,"type":31},"2025-02-15",{"date":312,"type":20},"2025-09-01",{"name":37,"class":38},{"id":315,"slug":316,"hasResults":11,"nctId":317,"briefTitle":318,"officialTitle":319,"acronym":4,"eligibilityCriteria":320,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":47,"enrollmentInfo":321,"targetDuration":4,"studyType":21,"phases":323,"briefSummary":324,"conditions":325,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":326,"lastUpdatePostDateStruct":327,"startDateStruct":329,"completionDateStruct":331,"leadSponsor":333,"locationsCount":39},"100573247","phase-4-the-effect-of-coenzyme-q10-in-preventing-pain-after-thoracoscopic-surgery-100573247","NCT06743802","The Effect of Coenzyme Q10 in Preventing Pain After Thoracoscopic Surgery","The Effect of Coenzyme Q10 in Preventing Pain After Thoracoscopic Surgery: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Aged 18-75 years;\n* American Society of Anesthesiology (ASA) physical status classification I-III;\n* Scheduled for elective lung resection surgery under thoracoscopy;\n* Voluntarily opting for patient-controlled intravenous analgesia;\n* Willing to participate in this trial after consultation with the patient or their family and signing the informed consent form.\n\nExclusion Criteria:\n\n* History of previous thoracotomy or thoracoscopic surgery;\n* Patients converted to open thoracotomy intraoperatively;\n* Severe hepatic or renal dysfunction;\n* History of substance abuse;\n* Pregnancy or breastfeeding;\n* History of chronic pain;\n* Use of coenzyme Q10 for more than one month;\n* Allergy to coenzyme Q10;\n* Patients unable to communicate or cooperate.",{"count":322,"type":20},264,[23],"This study aimed to assess the effectiveness of Coenzyme Q10 in preventing both acute and chronic pain following thoracoscopic surgery, with a focus on its potential benefits in reducing the incidence and severity of pain.",[236],"2025-02-25",{"date":328,"type":31},"2025-02-26",{"date":330,"type":31},"2025-01-09",{"date":332,"type":20},"2026-03-20",{"name":37,"class":38},{"id":335,"slug":336,"hasResults":11,"nctId":337,"briefTitle":338,"officialTitle":338,"acronym":4,"eligibilityCriteria":339,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":340,"targetDuration":4,"studyType":21,"phases":342,"briefSummary":343,"conditions":344,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":347,"lastUpdatePostDateStruct":348,"startDateStruct":350,"completionDateStruct":351,"leadSponsor":353,"locationsCount":148},"100538633","safety-and-effectiveness-of-sulfasalazine-in-the-treatment-of-liver-fibrosiscirrhosis-100538633","NCT06293378","Safety and Effectiveness of Sulfasalazine in the Treatment of Liver Fibrosis\u002FCirrhosis.","Inclusion Criteria:\n\n1. Sign the informed consent form before the trial and be able to complete the study in accordance with the requirements of the trial protocol;\n2. The age is 18\\~70 years old (including boundary value), the weight of male subjects is not less than 45 kg, and the weight of female subjects is not less than 40 kg. Body mass index (BMI) in the range of 18\\~32kg\u002Fm2 (including critical value);\n3. Enrolled patients also need to meet:\n\nA:Patients with PBC cirrhosis PBC patients who have been treated and show an inadequate response to UDCA：(1) according to the biochemical response criteria for 2021 PBC, Enrolled patients need to meet the criteria of ALP ≥1.67 × ULN as a poor biochemical response to UDCA after 12 months of UDCA treatment; (2) meeting the diagnostic criteria for primary cholangitis (PBC) , i.e. meeting at least two of the following criteria: 1.indicators of cholestasis such as elevated Alkaline phosphatase; 2.Anti-mitochondrial antibody AMA or AMA-m2 positive, or if AMA negative, PBC-specific antibodies (anti-GP210 Andor anti-SP100) positive .3 liver biopsy consistent with PBC; Patients with newly diagnosed primary cholangitis (PBC-RRB- met the diagnostic criteria of at least two of the following): 1.indicators of cholestasis such as elevated Alkaline phosphatase; 2.Anti-mitochondrial antibody AMA or AMA-m2 positive, or if AMA negative, PBC-specific antibodies (anti-GP210 Andor anti-SP100) positive 3. liver biopsy consistent with PBC; B:Patients with hepatitis B cirrhosis Diagnosis of hepatitis B cirrhosis based on clinical history, histology or imaging.\n\nC:Patients with hepatitis C cirrhosis Diagnosis of hepatitis C cirrhosis based on clinical history, histology or imaging.\n\nD:Alcoholic hepatitis cirrhosis Diagnosis of alcoholic cirrhosis based on clinical history, histology, or imaging.\n\nExclusion Criteria:\n\n1. Those who have a history of allergies in the past, or the investigator suspects that they are allergic to the active ingredients of the drug or their excipients under study;\n2. Allergy to sulfasalazine and its metabolites, sulfonamides or salicylic acid;\n3. Patients with intestinal obstruction or urinary tract obstruction;\n4. Patients with porphyria, such as sulfonamides, have been reported to cause acute attacks.\n5. Acute and chronic liver disease with clinical significance caused by infections other than HBV, HCV, PBC, and alcoholic liver disease;\n6. Primary liver cancer; alpha-fetoprotein (AFP) greater than 50 ug\u002FL or imaging suggests malignant liver mass; Those with other malignancies or a history of other malignancies in the 5 years prior to screening (except for complete remission of malignant tumors after treatment and no additional medical or surgical intervention within 3 years prior to screening);\n7. The investigator judged that there is impaired gastrointestinal function or gastrointestinal diseases that may affect the absorption of oral drugs, such as severe gastric ulcer, erosive gastritis, partial gastrectomy, and persistent \\>Grade 2 gastrointestinal symptoms (e.g., nausea, vomiting, or diarrhoea);\n8. Serious diseases of circulatory, respiratory, urinary, blood, metabolic, immune, psychiatric, neurological, renal and other systems;\n9. Those who have had major trauma or undergone major surgery within 3 months before screening; or those who plan to undergo surgery during the study;\n10. Donated blood or lost blood ≥ 400mL within 3 months before screening, or received blood transfusion; or ≥ blood donation or blood loss within 1 month prior to screening 200mL；\n11. Those who are positive for AIDS antigen\u002Fantibody, positive for Treponema pallidum antibody and positive RPR test;\n12. History of drug dependence or drug abuse within 1 year prior to screening;\n13. Participate in clinical trials of other investigational drugs or medical devices within 3 months before screening, and take experimental drugs or use them Those who have medical devices;\n14. Those who have a positive pregnancy test during lactation or screening, or who have fertility requirements in the past two years;\n15. Subjects who the investigator believes have other factors that are not suitable to participate in this trial.",{"count":341,"type":20},330,[101],"This is a controlled, observational clinical study initiated by investigators to investigate the efficacy and safety of sulfasalazine in the treatment of cirrhosis in patients with cirrhosis. Four cohorts were planned: primary biliary cirrhosis, hepatitis B and C cirrhosis, and alcoholic cirrhosis. The four groups were divided into experimental group and control group, and the experimental group: each group of patients was orally treated sulfasalazine for 12 months, taken three times a day, each time taking 0.5g. The control group did not take sulfasalazine. After 12 months, Observe changes in patients' biochemical and imaging indicators, liver stiffness values, fecal microbiota, and metabolites before and after the use of sulfasalazine.",[345,346],"Cirrhosis, Liver","Fibrosis, Liver","2025-02-18",{"date":349,"type":31},"2025-02-20",{"date":288,"type":31},{"date":352,"type":20},"2028-10-10",{"name":37,"class":38},{"id":355,"slug":356,"hasResults":11,"nctId":357,"briefTitle":358,"officialTitle":359,"acronym":4,"eligibilityCriteria":360,"healthyVolunteers":75,"sex":15,"minAge":16,"maxAge":361,"enrollmentInfo":362,"targetDuration":4,"studyType":21,"phases":364,"briefSummary":365,"conditions":366,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":371,"lastUpdatePostDateStruct":372,"startDateStruct":374,"completionDateStruct":376,"leadSponsor":378,"locationsCount":39},"100575675","the-effect-of-general-anesthesia-with-remimazolam-and-propofol-on-rhythmic-state-and-cognitive-function-100575675","NCT06775366","The Effect of General Anesthesia with Remimazolam and Propofol on Rhythmic State and Cognitive Function","Effects of General Anesthesia with Remimazolam and Propofol on Rhythmic State and Cognitive Function","Inclusion Criteria:\n\nAge 18-65 years old, ASAI-III class, BMI18.5-25kg\u002Fm2 Inpatients undergoing laparoscopic cholecystectomy The estimated time of operation is 1.5\\~2.5 hours Preoperative brief mental status examination (MMSE) score ≥24 Voluntary participation and signed informed consent\n\nExclusion Criteria:\n\nPregnant or lactating women Patients who are allergic to remimazolam or contraindicated Patients who are dependent on or tolerant to opioids or have long-term alcoholism Serious cardiovascular system, respiratory system, liver and kidney diseases History of obstructive sleep apnea mental disorders or neurological diseases Patients who participated in clinical trials of other drugs within the last 3 months The attending physician or researcher considers that there are other circumstances that are not suitable for participation in this study Refuse to participate in the study","65 Years",{"count":363,"type":20},174,[101],"This study want to observe the effects of remimazolam and propofol for general anesthesia on postoperative rhythm and cognitive function. The observation group was given remimazolam for general anesthesia, and the control group was given propofol for general anesthesia. Both drugs are commonly used as intravenous anesthetics for general anesthesia and have been shown to be safe for use in general anesthesia. The investigators hope can understand the effects of remimazolam and propofol for general anesthesia on rhythm status and cognitive function through this study, further reduce the occurrence of postoperative cognitive function impairment, and enable subjects to better recover.",[367,368,369,370],"Cognitive Functioning","Propofol","Remimazolam","Circadian Rhythm","2025-02-12",{"date":373,"type":31},"2025-02-14",{"date":375,"type":20},"2025-02-24",{"date":377,"type":20},"2026-05-30",{"name":37,"class":38},{"id":380,"slug":381,"hasResults":11,"nctId":382,"briefTitle":383,"officialTitle":383,"acronym":4,"eligibilityCriteria":384,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":385,"enrollmentInfo":386,"targetDuration":4,"studyType":21,"phases":388,"briefSummary":389,"conditions":390,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":392,"lastUpdatePostDateStruct":393,"startDateStruct":395,"completionDateStruct":397,"leadSponsor":399,"locationsCount":39},"100576249","the-effects-of-gma-tulip-i-gel-and-blockbuster-laryngeal-mask-in-surgeries-with-lateral-position-under-general-anesthesia-100576249","NCT06782841","The Effects of GMA-TULIP, I-gel, and BlockBuster Laryngeal Mask in Surgeries With Lateral Position Under General Anesthesia","Inclusion Criteria:\n\n1. Patients received surgeries in lateral position with an estimated surgery duration of less than 3 hours under general anesthesia.\n2. Ages between 18 to 80, and body mass index less than 28 kg\u002Fm².\n3. American Society of Anesthesiologists (ASA) Grades I-III.\n4. Patients are willing to participate and be able to understand and sign an informed consent form.\n\nExclusion Criteria:\n\n1. Individuals with an open bite of less than 2cm.\n2. Individuals with a history of obvious regurgitation of gastric contents and risk factors for aspiration.\n3. Patients with combined pharyngeal and laryngeal lesions.\n4. Predicting difficult airway patients.\n5. Hearing, intellectual, communication, and cognitive impairments.\n6. Any reason that prevents cooperation with the study or that the researcher deems inappropriate for inclusion in this trial.","80 Years",{"count":387,"type":20},102,[101],"To compare the efficacy and safety of traditional inflatable laryngeal mask, i-gel non-inflatable laryngeal mask and GMA-TULIP non-inflatable laryngeal mask in surgeries with lateral position under general anesthesia, so that providing evidence for the selection of laryngeal mask in surgeries with lateral position.",[391],"Oropharyngeal Leak Pressure","2025-01-14",{"date":394,"type":31},"2025-01-20",{"date":396,"type":31},"2024-08-21",{"date":398,"type":20},"2026-06-01",{"name":37,"class":38},{"id":401,"slug":402,"hasResults":11,"nctId":403,"briefTitle":404,"officialTitle":404,"acronym":4,"eligibilityCriteria":405,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":385,"enrollmentInfo":406,"targetDuration":4,"studyType":21,"phases":408,"briefSummary":409,"conditions":410,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":412,"lastUpdatePostDateStruct":413,"startDateStruct":414,"completionDateStruct":415,"leadSponsor":416,"locationsCount":39},"100574974","the-effects-of-gma-tulip-i-gel-and-blockbuster-laryngeal-mask-in-laparoscopic-surgeries-with-trendelenburg-position-under-general-anesthesia-100574974","NCT06766253","The Effects of GMA-TULIP, I-gel, and BlockBuster Laryngeal Mask in Laparoscopic Surgeries With Trendelenburg Position Under General Anesthesia","Inclusion Criteria:\n\n1. Patients received laparoscopic surgeries with trendelenburg position and an estimated surgery duration of less than 3 hours.\n2. Ages between 18 to 80, and body mass index less than 28 kg\u002Fm².\n3. American Society of Anesthesiologists (ASA) Grades I-III.\n4. Patients are willing to participate and be able to understand and sign an informed consent form.\n\nExclusion Criteria:\n\n1. Patients with a mouth opening less than 2 cm.\n2. Patients with risk factors for regurgitation and aspiration of gastric contents.\n3. Patients with laryngopharyngeal diseases.\n4. Patients with potentially difficult airways.\n5. Patients with hearing, intellectual, communication, and cognitive impairments.\n6. Any reason that patients could not cooperate with the study or that the researcher deems inappropriate for inclusion in this trial.",{"count":407,"type":20},195,[101],"This project aims to compare the application effects of traditional inflatable BlockBuster laryngeal mask, i-gel non-inflatable laryngeal mask and GMA-TULIP non-inflatable laryngeal mask in laparoscopic surgeries with trendelenburg position under general anesthesia, in order to explore which laryngeal mask is best for reducing postoperative throat pain of patients and improving patient comfort and satisfaction.",[411],"Sore-throat","2025-01-05",{"date":330,"type":31},{"date":396,"type":31},{"date":398,"type":20},{"name":37,"class":38},{"id":418,"slug":419,"hasResults":11,"nctId":420,"briefTitle":421,"officialTitle":421,"acronym":4,"eligibilityCriteria":422,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":423,"targetDuration":4,"studyType":21,"phases":425,"briefSummary":426,"conditions":427,"keywords":429,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":433,"lastUpdatePostDateStruct":434,"startDateStruct":436,"completionDateStruct":438,"leadSponsor":440,"locationsCount":39},"100537715","a-comparative-effect-of-echogenic-needle-for-nerve-block-on-acute-and-chronic-postoperative-pain-100537715","NCT06281431","A Comparative Effect of Echogenic Needle for Nerve Block on Acute and Chronic Postoperative Pain","Inclusion Criteria:\n\n1. The age is above 18 years old and below 70 years old.\n2. patients whose surgical sites were in the chest, abdomen, upper limbs or lower limbs, including lobectomy, cholecystectomy, gastrointestinal resection, hysterectomy and other elective operations.\n3. This operation was the first operation during the hospitalization.\n4. Consent to participate in this study and sign an informed consent form.\n\nExclusion Criteria:\n\n1. Patients with a history of alcohol or drug addiction.\n2. Patients with disturbance of consciousness before operation.\n3. Other conditions considered by the attending physician or researcher to be inappropriate for the study;\n4. History of chronic pain.\n5. Abnormal coagulation function.",{"count":424,"type":20},1000,[101],"Surgical pain is a common complication after surgery, affecting patient recovery and treatment quality. \\>20% of patients suffer from chronic postoperative pain. China has \\>70 million surgeries yearly. Nerve block manages postoperative pain, with developing nerve block needles now used in clinics. Developed needles may have better pain management effects than non-developed ones, but their effect on reducing chronic pain remains unclear. This study aims to explore the effect of developed nerve block needles on postoperative pain and compare them to non-developed needles, providing new ideas and methods for pain management.",[428],"Chronic Postoperative Pain",[430,431,432],"Visualized nerve block needle","Acute pain","Chronic pain","2024-08-13",{"date":435,"type":31},"2024-08-14",{"date":437,"type":31},"2023-06-12",{"date":439,"type":20},"2025-09-30",{"name":37,"class":38},{"id":442,"slug":443,"hasResults":11,"nctId":444,"briefTitle":445,"officialTitle":445,"acronym":4,"eligibilityCriteria":446,"healthyVolunteers":11,"sex":272,"minAge":447,"maxAge":448,"enrollmentInfo":449,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":451,"conditions":452,"keywords":453,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":433,"lastUpdatePostDateStruct":455,"startDateStruct":457,"completionDateStruct":459,"leadSponsor":461,"locationsCount":39},"100473572","circadian-rhythm-status-and-cs-cesarean-section-postoperative-pain-100473572","NCT05446636","Circadian Rhythm Status and CS (Cesarean Section) Postoperative Pain","Inclusion Criteria:\n\n* Age 20 to 45\n* ASA(American society of anesthesiologists) status II-III\n* 37-42 weeks gestation\n* undergo elective cesarean section with subarachnoid anesthesia\n* participate in this study and sign informed consent\n\nExclusion Criteria:\n\n* Patients with contraindications of combined spinal and epidural anesthesia\n* Patients with severe systemic disease\n* Alcoholism and long-term use of anti-inflammatory and analgesic drugs\n* Patients who were unable to cooperate or refused to participate in the trial\n* with psychiatric disorder\n* researchers considered unsuitable to participate in or unable to cooperate with the study","20 Years","45 Years",{"count":450,"type":20},280,"Use huawei wristwatch to record maternal rhythm status and record the VAS score after cesarean section under combined spinal-epidural anesthesia. Based on this study the investigators intend to explore the correlation between maternal circadian rhythm status and postoperative pain after cesarean section.",[370],[370,454,215],"Cesarean Section",{"date":456,"type":31},"2024-08-15",{"date":458,"type":31},"2023-02-14",{"date":460,"type":20},"2025-06",{"name":37,"class":38},{"id":463,"slug":464,"hasResults":11,"nctId":465,"briefTitle":466,"officialTitle":467,"acronym":468,"eligibilityCriteria":469,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":470,"targetDuration":471,"studyType":51,"phases":4,"briefSummary":472,"conditions":473,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":477,"lastUpdatePostDateStruct":478,"startDateStruct":480,"completionDateStruct":482,"leadSponsor":483,"locationsCount":39},"100556333","left-atrial-volume-changes-who-underwent-cardioversion-and-recurrence-of-af-after-rf-ablation-in-persistent-af-safe-af-100556333","NCT06523738","Left Atrial Volume Changes Who Underwent Cardioversion and Recurrence of AF After RF Ablation in Persistent AF (SAFE-AF)","Association of Left Atrial Volume Changes After Cardioversion and Recurrence of Atrial Fibrillation After Radiofrequency Ablation in Patients With Persistent Atrial Fibrillation","SAFE-AF-ABL","Inclusion Criteria:\n\n1. Patients with estabolished diagnosis of Persistent Atrial Fibrillation during past 6 mnths.\n2. LAD brfore entering the two cohorts is more than 40mm, and less than 50mm.\n3. Pharmacological or electrical cardioversion has be performed successfully.\n4. At least two echocardiograms were performed before and 3-6 months after cardioversion., and confirm the status of LAD (Reversal, unchange, enlargment).\n5. Patients have given informed consent.\n\nExclusion Criteria:\n\n1. Prior radiofrequency ablation treatment for atrial fibrillation\n2. Prior cardiac surgical procedures\n3. Individuals with cognitive impairments who are unable to give informed consent",{"count":99,"type":20},"24 Months","Electrical\u002Fpharmacological cardioversion improves structural remodeling of left atrium. We hypothesize that persistent atrial fibrillation (AF) patients with more significant left atrial size reduction after cardioversion have lower AF recurrence rates following radiofrequency ablation. The aim is to evaluate the relationship between changes in left atrial size 3 to 6 months after cardioversion and the recurrence rate of atrial fibrillation following radiofrequency ablation.",[474,475,476],"Persisent Atrial Fibrillation","Reversal of Atrial Enlargement","Recurrence of Atrial Fibrillation","2024-07-23",{"date":479,"type":31},"2024-07-26",{"date":481,"type":31},"2019-07-01",{"date":290,"type":20},{"name":37,"class":38},""]